Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer

Chia En Chang, Chien Ming Hsieh, Ling Chun Chen, Chia Yu Su, Der Zen Liu, Hua Jing Jhan, Hsiu O. Ho, Ming Thau Sheu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The synergistic combination of docetaxel (DTX) and cisplatin (CIS) by local drug delivery with a pluronic lecithin organogel (PLO) to facilitate high drug concentrations at tumor sites and less nonspecific distribution to normal organs is thought to be beneficial in chemotherapy. In this study, using Capryol- 90 (C90) with the addition of lecithin as the oil phase was developed to carry DTX, which was then incorporated into a PLO-containing CIS to formulate a dual-drug injectable PLO for local delivery. An optimal PLO composite, P13L0.15O1.5, composed of PF127:lecithin:C90 at a 13:0.15:1.5 weight ratio was obtained. The sol–gel transition temperature of P13L0.15O1.5 was found to be 33 °C. Tumor inhibition studies illustrated that DTX/CIS-loaded P13L0.15O1.5 could efficiently suppress tumor growth by both intratumoral and peritumoral injections in SKOV-3 xenograft mouse model. Pharmacokinetic studies showed that subcutaneous administration of P13L0.15O1.5 was able to sustain the release of DTX and CIS leading to their slow absorption into the systemic circulation resulting in lower area under the plasma concentration curve at 0–72 h (AUC0–72) and maximum concentration (Cmax) values but longer half-life (T1/2) and mean residence time (MRT) values. An in vivo biodistribution study showed lower DTX and CIS concentrations in organs compared to other treatment groups after IT administration of the dual drug-loaded P13L0.15O1.5. It was concluded that the local co-delivery of DTX and CIS by PLOs may be a promising and effective platform for local anticancer drug delivery with minimal systemic toxicities.

Original languageEnglish
Pages (from-to)632-643
Number of pages12
JournalDrug Delivery
Volume25
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

docetaxel
Poloxamer
Lecithins
Ovarian Neoplasms
Cisplatin
Pharmaceutical Preparations
Therapeutics
Neoplasms
Injections
Transition Temperature
Normal Distribution
Heterografts
Half-Life
Oils
Pharmacokinetics

Keywords

  • Cisplatin
  • Combination therapy
  • Docetaxel
  • Ovarian cancer
  • Pluronic lecithin organogel

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{048aca34db3b42d588ebd52b084a5115,
title = "Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer",
abstract = "The synergistic combination of docetaxel (DTX) and cisplatin (CIS) by local drug delivery with a pluronic lecithin organogel (PLO) to facilitate high drug concentrations at tumor sites and less nonspecific distribution to normal organs is thought to be beneficial in chemotherapy. In this study, using Capryol- 90 (C90) with the addition of lecithin as the oil phase was developed to carry DTX, which was then incorporated into a PLO-containing CIS to formulate a dual-drug injectable PLO for local delivery. An optimal PLO composite, P13L0.15O1.5, composed of PF127:lecithin:C90 at a 13:0.15:1.5 weight ratio was obtained. The sol–gel transition temperature of P13L0.15O1.5 was found to be 33 °C. Tumor inhibition studies illustrated that DTX/CIS-loaded P13L0.15O1.5 could efficiently suppress tumor growth by both intratumoral and peritumoral injections in SKOV-3 xenograft mouse model. Pharmacokinetic studies showed that subcutaneous administration of P13L0.15O1.5 was able to sustain the release of DTX and CIS leading to their slow absorption into the systemic circulation resulting in lower area under the plasma concentration curve at 0–72 h (AUC0–72) and maximum concentration (Cmax) values but longer half-life (T1/2) and mean residence time (MRT) values. An in vivo biodistribution study showed lower DTX and CIS concentrations in organs compared to other treatment groups after IT administration of the dual drug-loaded P13L0.15O1.5. It was concluded that the local co-delivery of DTX and CIS by PLOs may be a promising and effective platform for local anticancer drug delivery with minimal systemic toxicities.",
keywords = "Cisplatin, Combination therapy, Docetaxel, Ovarian cancer, Pluronic lecithin organogel, Cisplatin, Combination therapy, Docetaxel, Ovarian cancer, Pluronic lecithin organogel",
author = "Chang, {Chia En} and Hsieh, {Chien Ming} and Chen, {Ling Chun} and Su, {Chia Yu} and Liu, {Der Zen} and Jhan, {Hua Jing} and Ho, {Hsiu O.} and Sheu, {Ming Thau}",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/10717544.2018.1440444",
language = "English",
volume = "25",
pages = "632--643",
journal = "Drug Delivery",
issn = "1071-7544",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer

AU - Chang, Chia En

AU - Hsieh, Chien Ming

AU - Chen, Ling Chun

AU - Su, Chia Yu

AU - Liu, Der Zen

AU - Jhan, Hua Jing

AU - Ho, Hsiu O.

AU - Sheu, Ming Thau

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The synergistic combination of docetaxel (DTX) and cisplatin (CIS) by local drug delivery with a pluronic lecithin organogel (PLO) to facilitate high drug concentrations at tumor sites and less nonspecific distribution to normal organs is thought to be beneficial in chemotherapy. In this study, using Capryol- 90 (C90) with the addition of lecithin as the oil phase was developed to carry DTX, which was then incorporated into a PLO-containing CIS to formulate a dual-drug injectable PLO for local delivery. An optimal PLO composite, P13L0.15O1.5, composed of PF127:lecithin:C90 at a 13:0.15:1.5 weight ratio was obtained. The sol–gel transition temperature of P13L0.15O1.5 was found to be 33 °C. Tumor inhibition studies illustrated that DTX/CIS-loaded P13L0.15O1.5 could efficiently suppress tumor growth by both intratumoral and peritumoral injections in SKOV-3 xenograft mouse model. Pharmacokinetic studies showed that subcutaneous administration of P13L0.15O1.5 was able to sustain the release of DTX and CIS leading to their slow absorption into the systemic circulation resulting in lower area under the plasma concentration curve at 0–72 h (AUC0–72) and maximum concentration (Cmax) values but longer half-life (T1/2) and mean residence time (MRT) values. An in vivo biodistribution study showed lower DTX and CIS concentrations in organs compared to other treatment groups after IT administration of the dual drug-loaded P13L0.15O1.5. It was concluded that the local co-delivery of DTX and CIS by PLOs may be a promising and effective platform for local anticancer drug delivery with minimal systemic toxicities.

AB - The synergistic combination of docetaxel (DTX) and cisplatin (CIS) by local drug delivery with a pluronic lecithin organogel (PLO) to facilitate high drug concentrations at tumor sites and less nonspecific distribution to normal organs is thought to be beneficial in chemotherapy. In this study, using Capryol- 90 (C90) with the addition of lecithin as the oil phase was developed to carry DTX, which was then incorporated into a PLO-containing CIS to formulate a dual-drug injectable PLO for local delivery. An optimal PLO composite, P13L0.15O1.5, composed of PF127:lecithin:C90 at a 13:0.15:1.5 weight ratio was obtained. The sol–gel transition temperature of P13L0.15O1.5 was found to be 33 °C. Tumor inhibition studies illustrated that DTX/CIS-loaded P13L0.15O1.5 could efficiently suppress tumor growth by both intratumoral and peritumoral injections in SKOV-3 xenograft mouse model. Pharmacokinetic studies showed that subcutaneous administration of P13L0.15O1.5 was able to sustain the release of DTX and CIS leading to their slow absorption into the systemic circulation resulting in lower area under the plasma concentration curve at 0–72 h (AUC0–72) and maximum concentration (Cmax) values but longer half-life (T1/2) and mean residence time (MRT) values. An in vivo biodistribution study showed lower DTX and CIS concentrations in organs compared to other treatment groups after IT administration of the dual drug-loaded P13L0.15O1.5. It was concluded that the local co-delivery of DTX and CIS by PLOs may be a promising and effective platform for local anticancer drug delivery with minimal systemic toxicities.

KW - Cisplatin

KW - Combination therapy

KW - Docetaxel

KW - Ovarian cancer

KW - Pluronic lecithin organogel

KW - Cisplatin

KW - Combination therapy

KW - Docetaxel

KW - Ovarian cancer

KW - Pluronic lecithin organogel

UR - http://www.scopus.com/inward/record.url?scp=85046028431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046028431&partnerID=8YFLogxK

U2 - 10.1080/10717544.2018.1440444

DO - 10.1080/10717544.2018.1440444

M3 - Article

AN - SCOPUS:85046028431

VL - 25

SP - 632

EP - 643

JO - Drug Delivery

JF - Drug Delivery

SN - 1071-7544

IS - 1

ER -